Management of Pathologic Node-Positive Prostate Cancer following Radical Prostatectomy

Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2022. CA: a cancer journal for clinicians. 2022;72(1):7–33.

Carter HB, Albertsen Peter C, Barry Michael J, et al. Early detection of prostate cancer: AUA guideline. J Urol. 2013;190:419–26.

Article  PubMed  PubMed Central  Google Scholar 

Eastham James A, Auffenberg Gregory B, Barocas Daniel A, et al. Clinically localized prostate cancer: AUA/ASTRO guideline, Part I: introduction, risk assessment, staging, and risk-based management. J Urol. 2022;208:10–8.

Article  CAS  PubMed  Google Scholar 

Abdollah F, Suardi N, Gallina A, Bianchi M, Tutolo M, Passoni N, Fossati N, Sun M, dell’Oglio P, Salonia A, Karakiewicz PI, Rigatti P, Montorsi F, Briganti A. Extended pelvic lymph node dissection in prostate cancer: a 20-year audit in a single center. Ann Oncol. 2013;24(6):1459–66. https://doi.org/10.1093/annonc/mdt120.

Article  CAS  PubMed  Google Scholar 

Bernstein Adrien N, Shoag Jonathan E, Golan R, et al. Contemporary incidence and outcomes of prostate cancer lymph node metastases. J Urol. 2018;199:1510–7.

Article  CAS  PubMed  Google Scholar 

Marra G, Valerio M, Heidegger I, Tsaur I, Mathieu R, Ceci F, Ploussard G, van den Bergh RCN, Kretschmer A, Thibault C, Ost P, Tilki D, Kasivisvanathan V, Moschini M, Sanchez-Salas R, Gontero P, Karnes RJ, Montorsi F, Gandaglia G; EAU-YAU prostate cancer working party. Management of patients with node-positive prostate cancer at radical prostatectomy and pelvic lymph node dissection: a systematic review. Eur Urol Oncol. 2020;3(5):565–581. https://doi.org/10.1016/j.euo.2020.08.005.

National Comprehensive Cancer Network. Prostate Cancer (Version 1.2023). https://www.nccn.org/professionals/physician_gls/pdf/prostate.pdf. Accessed Oct. 20, 2022.

EAU (European Association of Urology) Guidelines. Prostate Cancer. https://d56bochluxqnz.cloudfront.net/documents/full-guideline/EAU-EANM-ESTRO-ESUR-ISUP_SIOG-Guidelines-on-Prostate-Cancer-2022_2022-04-25-063938_yfos.pdf. Accessed Oct. 20, 2022.

Touijer KA, Karnes RJ, Passoni N, et al. Survival outcomes of men with lymph node-positive prostate cancer after radical prostatectomy: a comparative analysis of different postoperative management strategies. Eur Urol. 2018;73(6):890–6.

Article  PubMed  Google Scholar 

Messing EM, Manola J, Sarosdy M, Wilding G, Crawford ED, Trump D. Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer. N Engl J Med. 1999;341(24):1781–8. https://doi.org/10.1056/NEJM199912093412401.

Article  CAS  PubMed  Google Scholar 

Messing EM, Manola J, Yao J, et al. Immediate versus deferred androgen deprivation treatment in patients with node-positive prostate cancer after radical prostatectomy and pelvic lymphadenectomy. Lancet Oncol. 2006;7(6):472–9.

Article  CAS  PubMed  Google Scholar 

Touijer KA, Mazzola CR, Sjoberg DD, Scardino PT, Eastham JA. Long-term outcomes of patients with lymph node metastasis treated with radical prostatectomy without adjuvant androgen-deprivation therapy. Eur Urol. 2014;65(1):20–5. https://doi.org/10.1016/j.eururo.2013.03.053.

Article  PubMed  Google Scholar 

Dorin RP, Lieskovsky G, Fairey AS, Cai J, Daneshmand S. Outcomes after radical prostatectomy for patients with clinical stages T1–T2 prostate cancer with pathologically positive lymph nodes in the prostate-specific antigen era. Urol Oncol. 2013;31(8):1441–7.

Article  PubMed  Google Scholar 

Mandel P, Kriegmair MC, Bogdan K, et al. Association between lymph node counts and oncological outcomes in lymph node positive prostate cancer. (2405–4569 (Electronic)).

Palapattu GS, Allaf ME, Trock BJ, Epstein JI, Walsh PC. Prostate specific antigen progression in men with lymph node metastases following radical prostatectomy: results of long-term followup. J Urol. 2004;172(5 Pt 1):1860–4. https://doi.org/10.1097/01.ju.0000139886.25848.4a.

Article  PubMed  Google Scholar 

Fleischmann A, Schobinger S, Schumacher M, Thalmann GN, Studer UE. Survival in surgically treated, nodal positive prostate cancer patients is predicted by histopathological characteristics of the primary tumor and its lymph node metastases. Prostate. 2009;69(4):352–62. https://doi.org/10.1002/pros.20889.

Article  PubMed  Google Scholar 

Huggins C, Hodges CV. Studies on prostatic cancer. I. The effect of castration, of estrogen and androgen injection on serum phosphatases in metastatic carcinoma of the prostate. CA Cancer J Clin. 1972;22(4):232–40.

Article  CAS  PubMed  Google Scholar 

Breul J, Lundström E, Purcea D, et al. Efficacy of testosterone suppression with sustained-release triptorelin in advanced prostate cancer. Adv Ther. 2017;34(2):513–23.

Article  CAS  PubMed  Google Scholar 

Nguyen PL, Alibhai SM, Basaria S, et al. Adverse effects of androgen deprivation therapy and strategies to mitigate them. Eur Urol. 2015;67(5):825–36.

Article  CAS  PubMed  Google Scholar 

Wong YN, Freedland S, Egleston B, Hudes G, Schwartz JS, Armstrong K. Role of androgen deprivation therapy for node-positive prostate cancer. J Clin Oncol. 2009;27(1):100–5.

Article  PubMed  Google Scholar 

Park S, Kim SC, Kim W, Song C, Ahn H. Impact of adjuvant androgen-deprivation therapy on disease progression in patients with node-positive prostate cancer. Korean J Urol. 2011;52(11):741–5.

Article  PubMed  PubMed Central  Google Scholar 

Broughman JR, Chen RC. Management of node-positive and oligometastatic prostate cancer. Semin Radiat Oncol. 2017;27:79–86.

Article  PubMed  Google Scholar 

Zagars GK, Pollack A, von Eschenbach AC. Addition of radiation therapy to androgen ablation improves outcome for subclinically node-positive prostate cancer. Urology. 2001;58:233–9.

Article  CAS  PubMed  Google Scholar 

• Guo L, Zhu Z, Zhang X. Adding radiotherapy to androgen deprivation therapy in men with node-positive prostate cancer after radical prostatectomy: a meta-analysis. Medicine. 2020;99(10). This study highlights that the addition of adjuvant radiation therapy to a regimen of adjuvant androgen deprivation therapy may be associated with improved overall survival and cancer specific survival.

Lin CC, Gray PJ, Jemal A, Efstathiou JA. Androgen deprivation with or without radiation therapy for clinically node-positive prostate cancer. JNCI: J Nat Cancer Inst. 2015;107:djv119.

Rusthoven CG, Carlson JA, Waxweiler TV, Raben D, Dewitt PE, Crawford ED, Maroni PD, Kavanagh BD. The impact of definitive local therapy for lymph node-positive prostate cancer: a population-based study. Int J Radiat Oncol Biol Phys. 2014;88(5):1064–73. https://doi.org/10.1016/j.ijrobp.2014.01.008.

Article  PubMed  Google Scholar 

Tilki D, Preisser F, Tennstedt P, Tober P, Mandel P, Schlomm T, Steuber T, Huland H, Schwarz R, Petersen C, Graefen M, Ahyai S. Adjuvant radiation therapy is associated with better oncological outcome compared with salvage radiation therapy in patients with pN1 prostate cancer treated with radical prostatectomy. BJU Int. 2017;119(5):717–23. https://doi.org/10.1111/bju.13679.

Article  CAS  PubMed  Google Scholar 

•• Tilki D, Chen MH, Wu J, Huland H, Graefen M, D'Amico AV. Adjuvant versus early salvage radiation therapy after radical prostatectomy for pN1 prostate cancer and the risk of death. J Clin Oncol. 2022;40(20):2186–2192. https://doi.org/10.1200/JCO.21.02800. This article compares adjuvant radiation therapy to salvage radiation therapy and reports decreased all cause mortality with the use of adjuvant radiation therapy.

留言 (0)

沒有登入
gif